Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells: first results of the SUCCESS C endocrine treatment sub-study
Background: ptimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing. Patients and Methods: Postmenopausal women with HER2-negative, hormone receptor-po...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 27, 2018
|
| In: |
Oncology research and treatment
Year: 2018, Volume: 41, Issue: 3, Pages: 93-98 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000485566 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000485566 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/485566 
|
| Author Notes: | Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, Arkadius Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni-Fabbroni, Andreas Schneeweiss, Volkmar Müller, Klaus Pantel, Jörg Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, Werner Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Thomas W. P. Friedl, on behalf of the SUCCESS Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694293912 | ||
| 003 | DE-627 | ||
| 005 | 20220818034223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200408s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000485566 |2 doi | |
| 035 | |a (DE-627)1694293912 | ||
| 035 | |a (DE-599)KXP1694293912 | ||
| 035 | |a (OCoLC)1341314323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schochter, Fabienne |e VerfasserIn |0 (DE-588)1207953997 |0 (DE-627)1694294129 |4 aut | |
| 245 | 1 | 0 | |a Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells |b first results of the SUCCESS C endocrine treatment sub-study |c Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, Arkadius Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni-Fabbroni, Andreas Schneeweiss, Volkmar Müller, Klaus Pantel, Jörg Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, Werner Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Thomas W. P. Friedl, on behalf of the SUCCESS Study Group |
| 264 | 1 | |c February 27, 2018 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: February 27, 2018 | ||
| 500 | |a Gesehen am 08.04.2020 | ||
| 520 | |a Background: ptimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing. Patients and Methods: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups.Results: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups. Conclusion: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis. | ||
| 700 | 1 | |a Rack, Brigitte K. |d 1975- |e VerfasserIn |0 (DE-588)128780479 |0 (DE-627)379681420 |0 (DE-576)297329340 |4 aut | |
| 700 | 1 | |a Tzschaschel, Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Polasik, Arkadius |e VerfasserIn |4 aut | |
| 700 | 1 | |a Andergassen, Ulrich |e VerfasserIn |0 (DE-588)1044064897 |0 (DE-627)771381271 |0 (DE-576)396674461 |4 aut | |
| 700 | 1 | |a Trapp, Elisabeth |e VerfasserIn |0 (DE-588)1163773492 |0 (DE-627)1028137168 |0 (DE-576)508218764 |4 aut | |
| 700 | 1 | |a Alunni-Fabbroni, Marianna |e VerfasserIn |0 (DE-588)115665968X |0 (DE-627)1019500115 |0 (DE-576)502357525 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Müller, Volkmar |d 1967- |e VerfasserIn |0 (DE-588)12133497X |0 (DE-627)081238053 |0 (DE-576)292653719 |4 aut | |
| 700 | 1 | |a Pantel, Klaus |d 1960- |e VerfasserIn |0 (DE-588)1027683606 |0 (DE-627)729554929 |0 (DE-576)373549997 |4 aut | |
| 700 | 1 | |a Gade, Jörg |d 1962- |e VerfasserIn |0 (DE-588)122519450 |0 (DE-627)705937275 |0 (DE-576)293305293 |4 aut | |
| 700 | 1 | |a Lorenz, Ralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rezai, Mahdi |d 1953- |e VerfasserIn |0 (DE-588)1107970350 |0 (DE-627)863713580 |0 (DE-576)475152131 |4 aut | |
| 700 | 1 | |a Tesch, Hans |e VerfasserIn |0 (DE-588)1020286687 |0 (DE-627)688112129 |0 (DE-576)360062873 |4 aut | |
| 700 | 1 | |a Soeling, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fehm, Tanja |d 1971- |e VerfasserIn |0 (DE-588)120391759 |0 (DE-627)080645690 |0 (DE-576)292194064 |4 aut | |
| 700 | 1 | |a Mahner, Sven |d 1975- |e VerfasserIn |0 (DE-588)130244775 |0 (DE-627)495828009 |0 (DE-576)29808466X |4 aut | |
| 700 | 1 | |a Schindlbeck, Christian |d 1968- |e VerfasserIn |0 (DE-588)121895599 |0 (DE-627)081605188 |0 (DE-576)292943903 |4 aut | |
| 700 | 1 | |a Lichtenegger, Werner |e VerfasserIn |0 (DE-588)123140811 |0 (DE-627)516179071 |0 (DE-576)293573964 |4 aut | |
| 700 | 1 | |a Beckmann, Matthias Wilhelm |d 1960- |e VerfasserIn |0 (DE-588)112832776 |0 (DE-627)521405378 |0 (DE-576)289744059 |4 aut | |
| 700 | 1 | |a Fasching, Peter Andreas |d 1975- |e VerfasserIn |0 (DE-588)129068780 |0 (DE-627)388703040 |0 (DE-576)297477099 |4 aut | |
| 700 | 1 | |a Janni, Wolfgang |e VerfasserIn |0 (DE-588)135832640 |0 (DE-627)57224651X |0 (DE-576)300670370 |4 aut | |
| 700 | 1 | |a Friedl, Thomas W. P. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 41(2018), 3, Seite 93-98 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells first results of the SUCCESS C endocrine treatment sub-study |
| 773 | 1 | 8 | |g volume:41 |g year:2018 |g number:3 |g pages:93-98 |g extent:6 |a Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells first results of the SUCCESS C endocrine treatment sub-study |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000485566 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/485566 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200408 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 8 | ||
| 999 | |a KXP-PPN1694293912 |e 3620710961 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1694293912"],"doi":["10.1159/000485566"]},"physDesc":[{"extent":"6 S."}],"title":[{"title_sort":"Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells","title":"Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells","subtitle":"first results of the SUCCESS C endocrine treatment sub-study"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"February 27, 2018"}],"relHost":[{"recId":"776629611","origin":[{"publisherPlace":"Basel","dateIssuedKey":"2014","dateIssuedDisp":"2014-","publisher":"Karger"}],"title":[{"title_sort":"Oncology research and treatment","title":"Oncology research and treatment"}],"id":{"zdb":["2749752-5"],"eki":["776629611"],"issn":["2296-5262"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 15.12.2023"],"pubHistory":["37.2014 -"],"language":["eng"],"part":{"year":"2018","volume":"41","extent":"6","pages":"93-98","issue":"3","text":"41(2018), 3, Seite 93-98"},"disp":"Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells first results of the SUCCESS C endocrine treatment sub-studyOncology research and treatment","type":{"bibl":"periodical","media":"Online-Ressource"}}],"language":["eng"],"name":{"displayForm":["Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, Arkadius Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni-Fabbroni, Andreas Schneeweiss, Volkmar Müller, Klaus Pantel, Jörg Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, Werner Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Thomas W. P. Friedl, on behalf of the SUCCESS Study Group"]},"note":["Published online: February 27, 2018","Gesehen am 08.04.2020"],"recId":"1694293912","person":[{"role":"aut","family":"Schochter","display":"Schochter, Fabienne","given":"Fabienne"},{"given":"Brigitte K.","display":"Rack, Brigitte K.","family":"Rack","role":"aut"},{"given":"Marie","display":"Tzschaschel, Marie","role":"aut","family":"Tzschaschel"},{"family":"Polasik","role":"aut","given":"Arkadius","display":"Polasik, Arkadius"},{"given":"Ulrich","display":"Andergassen, Ulrich","family":"Andergassen","role":"aut"},{"role":"aut","family":"Trapp","given":"Elisabeth","display":"Trapp, Elisabeth"},{"family":"Alunni-Fabbroni","role":"aut","given":"Marianna","display":"Alunni-Fabbroni, Marianna"},{"family":"Schneeweiss","role":"aut","display":"Schneeweiss, Andreas","given":"Andreas"},{"family":"Müller","role":"aut","given":"Volkmar","display":"Müller, Volkmar"},{"given":"Klaus","display":"Pantel, Klaus","role":"aut","family":"Pantel"},{"family":"Gade","role":"aut","display":"Gade, Jörg","given":"Jörg"},{"given":"Ralf","display":"Lorenz, Ralf","family":"Lorenz","role":"aut"},{"family":"Rezai","role":"aut","given":"Mahdi","display":"Rezai, Mahdi"},{"given":"Hans","display":"Tesch, Hans","family":"Tesch","role":"aut"},{"given":"Ulrike","display":"Soeling, Ulrike","role":"aut","family":"Soeling"},{"role":"aut","family":"Fehm","display":"Fehm, Tanja","given":"Tanja"},{"role":"aut","family":"Mahner","given":"Sven","display":"Mahner, Sven"},{"role":"aut","family":"Schindlbeck","given":"Christian","display":"Schindlbeck, Christian"},{"given":"Werner","display":"Lichtenegger, Werner","family":"Lichtenegger","role":"aut"},{"display":"Beckmann, Matthias Wilhelm","given":"Matthias Wilhelm","family":"Beckmann","role":"aut"},{"family":"Fasching","role":"aut","given":"Peter Andreas","display":"Fasching, Peter Andreas"},{"role":"aut","family":"Janni","given":"Wolfgang","display":"Janni, Wolfgang"},{"display":"Friedl, Thomas W. P.","given":"Thomas W. P.","role":"aut","family":"Friedl"}]} | ||
| SRT | |a SCHOCHTERFENDOCRINET2720 | ||